Navamedic ASA (OSL:NAVA)

Market Cap	379.75M
Revenue (ttm)	542.59M
Net Income (ttm)	-10.95M
Shares Out	17.66M
EPS (ttm)	n/a
PE Ratio	n/a
Forward PE	25.75
Dividend	n/a
Ex-Dividend Date	n/a

Volume	49,309
Average Volume	4,887
Open	21.80
Previous Close	21.50
Day's Range	21.50 - 22.00
52-Week Range	17.10 - 35.00
Beta	0.37
RSI	47.96
Earnings Date	Aug 14, 2025

About Navamedic ASA

Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Northern Europe. The company's product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic acidemia/propionic acidemia, glutaric aciduria, isovaleric acidemia...

• Industry: Medical Distribution
• Sector: Healthcare
• Founded: 2002
• Employees: 42
• Stock Exchange: Oslo Børs
• Ticker Symbol: NAVA

Financial Performance

In 2024, Navamedic ASA's revenue was 531.44 million, an increase of 3.80% compared to the previous year's 512.00 million. Losses were -5.49 million, -59.92% less than in 2023.